Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical mitomycin C with or without maintenance, and BCG-based regimens after TURBT for superficial bladder cancer
2009-010579-26Phase 2Active
- Sponsor
- Julio A Virseda Rodriguez
- Start
- Jul 2009
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of mitomycin c and bcg vaccine in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Julio A Virseda Rodriguez. Primary endpoints: Progression-free rate at 3 to 6 months, Progression-free survival and 1 more. Started Jul 2009; status: active.
02
Drugs
mitomycin cbcg vaccine
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2009-010579-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010579-26.